Trial Profile
MultiStem Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Invimestrocel (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms MASTERS-2
- Sponsors Athersys
- 10 Oct 2023 Results presented in an Athersys Media Release.
- 10 Oct 2023 According to an Athersys media release, company concluded current sample size of 300 patients is insufficiently powered to achieve primary endpoint of mRS Shift analysis at Day 365.There were no safety issues identified.Because sample size required to achieve statistical significance is considerably larger, company intends to conduct additional data analysis with independent statisticians and plans to pause enrollment of new patients while this analysis is being conducted.
- 10 Oct 2023 Status changed to suspended, according to an Athersys media release.